Bipolar II Disorder

Clinical picture

• Patients present in depression and rarely report hypomania spontaneously, because they experience it as feeling well or being productive.
• Hypomania appears as reduced sleep need with sustained energy, increased talkativeness, and uncharacteristic confidence noticed by others.
• Collateral history from partners and family is often the only reliable route to identifying past hypomanic periods.
• Depressive episodes are more frequent, longer, and more treatment-resistant than in unipolar illness, with atypical features common.
• Interepisode subsyndromal depression occupies roughly half of follow-up time and drives most of the functional impairment.
• Antidepressant-associated agitation, insomnia, or new irritability frequently signals previously unrecognized bipolarity.

Criteria snapshot

• Requires at least one hypomanic episode lasting four or more consecutive days and at least one major depressive episode.
• Hypomania involves elevated or irritable mood plus increased activity with three additional symptoms, or four if mood is only irritable.
• The mood and activity change must be observable by others and represent an unequivocal difference from the person's usual functioning.
• Hypomania must not cause marked impairment, require hospitalization, or include psychosis; any of these makes the episode manic instead.
• A single lifetime manic episode reclassifies the case as Bipolar I; Bipolar II is not a milder variant but a distinct longitudinal course.

Neurobiology

• Genetic loading and heritability approach those of Bipolar I, with substantial familial overlap between the two diagnostic categories.
• Circadian instability and abnormal sleep architecture predict episode onset and remain measurable even during euthymic intervals.
• Reward circuitry hypersensitivity to goal attainment underlies hypomanic activation following success, praise, or other reinforcement.
• Amygdala-prefrontal connectivity deficits parallel those of Bipolar I but with less pronounced structural change on neuroimaging.
• Thyroid dysfunction, particularly subclinical hypothyroidism, is overrepresented and worsens rapid cycling when left untreated.
• Cardiometabolic comorbidity and elevated all-cause mortality mirror Bipolar I despite the absence of full manic episodes.

Psychology

• Hypomania is ego-syntonic and often valued, producing systematic underreporting and diagnostic delays that average more than a decade.
• Behavioral activation system sensitivity links reward pursuit and ambitious goal striving to escalation of hypomanic symptoms.
• Rumination during depression and positive rumination during hypomania both amplify and prolong whichever state prevails.
• Shame about hypomanic-phase decisions, spending, or infidelity intensifies the self-attack of the subsequent depressive episode.
• Routine disruption, long-haul travel, and shift work destabilize biological rhythms and are direct psychotherapeutic targets.

Differential & comorbidity

• Most cases are initially misdiagnosed as unipolar depression; screen every depressed patient with the MDQ or a careful hypomania timeline.
• Borderline personality disorder features hours-long, interpersonally triggered shifts without sustained reduction in the need for sleep.
• Cyclothymic disorder never reaches full major depressive or hypomanic criteria, whereas Bipolar II requires both thresholds be met.
• Anxiety disorders, substance use disorders, eating disorders, and ADHD are highly comorbid and complicate pharmacologic management.
• Suicide attempt rates equal or exceed those in Bipolar I and carry high lethality, with depressive and mixed states at peak risk.

Pharmacologic treatment

• Quetiapine 300-600 mg/day carries the strongest randomized evidence for acute bipolar II depression and for maintenance treatment.
• Lithium 0.6-1.0 mEq/L and lamotrigine 100-200 mg/day are preferred maintenance options, with lamotrigine for depressive predominance.
• Lurasidone 20-120 mg/day treats bipolar depression with low metabolic burden; give with at least 350 calories to ensure absorption.
• Antidepressant monotherapy is not recommended; if used at all, pair it with a mood stabilizer and monitor for switching and cycle acceleration.
• Screen thyroid, renal function, and a metabolic panel at baseline, then check lithium levels every 3 to 6 months once the patient is stable.

Psychotherapy

• IPSRT protects sleep-wake and social rhythms, making it the modality most closely aligned with the disorder's circadian mechanism.
• Psychoeducation covering prodromes, early warning signs, and adherence reduces recurrence across roughly 12 to 21 sessions.
• CBT addresses depressive cognition and residual symptoms, which dominate the long interepisode periods in this population.
• Family-focused therapy lowers expressed emotion and improves depressive outcomes in both adolescents and adults.
• Therapy should explicitly map each patient's individual hypomanic signature so that early phases can be recognized and acted on.

Adjunct options

• Daily mood charting is more diagnostically informative in this disorder than any single cross-sectional clinical interview.
• Sleep regularization, limited alcohol use, and caffeine reduction help prevent rhythm-driven episode onset and cycling.
• rTMS and ECT are options for refractory bipolar depression, delivered with mood-stabilizer cover to reduce switch risk.
• Bright light therapy delivered in the midday window shows benefit for bipolar depression with relatively low switch rates.
• Discuss reproductive planning early given valproate and carbamazepine teratogenicity and the need for prepregnancy regimen changes.

Clinical pearls

• Hypomania feels good; patients report the depressions and hide the highs.
• Bipolar II is not mild; suicide risk matches or exceeds Bipolar I.
• Four days, not seven, and no functional collapse defines hypomania.